# Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

> **NCT03920072** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Pharmaceutical Development Ltd** · enrollment: 35 (actual)

## Conditions studied

- X-linked Hypophosphatemia

## Interventions

- **DRUG:** Burosumab

## Key facts

- **NCT ID:** NCT03920072
- **Lead sponsor:** Kyowa Kirin Pharmaceutical Development Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-07
- **Primary completion:** 2022-04-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920072, "Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03920072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*